- Home
- PANW vs MRK Comparison
PANW vs MRK Comparison
Compare PANW & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PANW | MRK |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.5B | 281.2B |
| IPO Year | 2012 | 1994 |
Fundamental Metrics
Financial Performance| Metric | PANW | MRK |
|---|---|---|
| Price | $301.85 | $127.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 39 | 17 |
| Target Price | ★ $216.28 | $125.59 |
| AVG Volume (30 Days) | 8.0M | ★ 8.6M |
| Earning Date | 05-19-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 3.06% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | ★ 0.79 | N/A |
| Revenue | $2,273,100,000.00 | ★ $65,011,000,000.00 |
| Revenue This Year | $24.93 | $3.61 |
| Revenue Next Year | $19.97 | $5.41 |
| P/E Ratio | $370.17 | ★ N/A |
| Revenue Growth | ★ 29.04 | 1.31 |
| 52 Week Low | $139.57 | $76.66 |
| 52 Week High | $302.95 | $125.96 |
Technical Indicators
Market Signals| Indicator | PANW | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 69.57 | 70.38 |
| Support Level | $179.81 | $112.68 |
| Resistance Level | $302.95 | N/A |
| Average True Range (ATR) | 11.33 | 3.07 |
| MACD | -0.85 | 0.91 |
| Stochastic Oscillator | 99.51 | 97.44 |
Price Performance
Historical ComparisonAbout PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three-fourths of the Global 2000.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).